Immune-Modifying Nanoparticle Therapy Fast Tracked for Primary Biliary Cholangitis
The Food and Drug Administration (FDA) has granted Fast Track designation to CNP-104 for the treatment of primary biliary cholangitis (PBC). Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by immune-mediated destruction…